Vice-President
SpringWorks Therapeutics
Ana B. Oton is a Medical Oncologist/Hematologist and currently VP of Nirogacestat Global Medical Affairs at SpringWorks since December 2019. She drives the Global Medical strategy for the nigoracestat franchise. Ana was born in Spain but she spent most of her young life in Venezuela where she obtained her Medical Degree at the Universidad Central de Venezuela in Caracas. She completed her Hematology/Oncology fellowship training at the University of Pittsburgh and joined the University of Colorado Denver and Denver Health Medical Center as faculty. Ana had a dual appointment with clinical, teaching and research responsibilities at both institutions. She became Associate Professor at the University of Colorado and Director of the Medical Oncology Research Program and Chair of the Cancer Committee at Denver Health Medical Center. In 2014, Ana made the transition to pharmaceutical industry and joined Eli Lilly as Medical Affairs Thoracic Malignancies Lead while she continued patient care at Denver Health Medical Center (Ana left clinical practice in 2018). During her time at Lilly, Ana led the launch and strategy development and execution of Medical Affairs programs for the US and Globally for the multi product-Thoracic Malignancies franchise. Ana transitioned to Late Phase Clinical Development in 2018 where she had multiple responsibilities including, leading the global development of phase I-IV clinical trials, product life cycle plans and strategy for external partnerships. She also supported all product-specific safety and US and global regulatory needs from the medical perspective.